What we do Natco Pharma is a research-driven pharmaceutical company specializing in finished dosage formulations and active pharmaceutical ingredients, serving niche and complex therapies globally. |
Founded in 1,981 |
Market share Leader in niche and complex generic formulations with strong presence in US, India, and emerging markets; recognized for Para IV FDA filings. |
Problem solved Provides affordable generic alternatives for complex and high-cost therapies including oncology, cardiology, hepatitis C, and other chronic diseases. |
Top clients or who we serve Serves healthcare providers, hospitals, and pharma distributors across B2B and B2C channels primarily in the USA, India, and international markets. |
Key management Rajeev Nannapaneni (Vice Chairman & CEO) and V.C. Nannapaneni (Chairman & MD) lead with strong industry expertise; board includes seasoned independent directors. |
Our journey and innovations Since 1981, expanded from APIs to formulations, pioneering compulsory licenses in India and launching first generics of blockbuster drugs globally. |
Where we operate Operates in over 40 countries including the USA, India, Europe, Brazil, Canada, Australia, Philippines, South Africa, Taiwan, and others. |
Top products or what we offer Flagship oncology drugs like Veenat, hepatitis C generics Hepcinat and Velpanat, cardiology and diabetology formulations, and broad-spectrum agrochemicals. |
Top brands Veenat (#1 generic Imatinib), Hepcinat (generic Sofosbuvir), Velpanat (Sofosbuvir/Velpatasvir), NATGEN and NATERRA pesticides, multiple Para IV FDA approved generics. |
Raw materials needed Active pharmaceutical ingredients, advanced chemical compounds, peptides, solvents, and excipients for formulations and APIs. |
Raw materials supplier Supplies raw materials internally through backward integrated API manufacturing and external vendors for specialized compounds. |
Recurring vs cyclical contribution Revenue largely recurring from sustained generic drug sales and long-term formulations supply with stable export and domestic markets. |
Our industry position Among top Indian pharma companies excelling in niche generics with strong US FDA approvals and aggressive global expansion in formulations and APIs. |
Financial highlights FY25 revenue INR 4429.5 Crores, PAT INR 1885.4 Crores; strong EBITDA margins (~46% Q2 FY26); robust cash reserves INR 3903 Crores. |
Geographical revenue split Revenue primarily from USA (70%), India (12%), and Rest of World (16%) showcasing diversified global footprint. |
Order book - |
Whats driving growth Growth driven by approvals of complex generics, expanding export formulations, R&D pipeline in oncology and infectious diseases, and agrochemical launch. |
Our future plans Expanding subsidiaries in South Africa, Indonesia, UK, and Colombia; enhancing cardiology and infectious disease portfolio; advancing cell and gene therapy R&D. |
Our green promise Committed to energy saving, water conservation, controlled emissions, and sustainable manufacturing across operations. |
Our people and values Employs skilled workforce fostering innovation, ethical conduct, diversity and inclusion with structured corporate governance. |
Key challenges ahead Regulatory risks, competition in generics market, patent challenges, and managing R&D investments amid evolving pharma landscape. |
Interesting facts First Indian company to launch generic Sofosbuvir in Nepal; pioneering compulsory license for cancer drug Nexavar in India. |
Risks and strategy Mitigates patent litigations and regulatory approvals risks via strong legal, compliance teams and diversified product pipeline with niche therapies. |
